

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

10/517097

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number  
WO 03/104274 A1

(51) International Patent Classification<sup>7</sup>: C07K 14/435,  
A61K 38/17

(FR). PIMENTA, Adriano Monteiro de Castro Pimenta  
[BR/BR]; Rua Marechal Hermes 810/302, 30430-030  
Bairro Gutierrez, Belo Hruzonte (BR).

(21) International Application Number: PCT/BR03/00073

(22) International Filing Date: 9 June 2003 (09.06.2003)

(74) Agent: DE ALMEIDA, Kátia, Fernandes; Behring,  
Almeida & Associados, Rua Beneditinos 16, 11o. Andar,  
CPE-20081-050 Rio de Janeiro, RJ (BR).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PI 0202157-9 7 June 2002 (07.06.2002) BR

(71) Applicant (for all designated States except US): UNIVER-  
SIDADE FEDERAL DE MINAS GERAIS [BR/BR];  
Avenida Antonio Carlos, 6627, Reitoria 7º andar sala  
7005, CEP-31270-901 Belo Horizonte, MG (BR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PEREZ-GARCIA,  
Maria Elena de Lima [BR/BR]; Avenida Coronel José  
Dias Bicalho 516/101, Bairro São Luiz, 31275-050 Belo  
Horizonte, Minas Gerais (BR). DINIZ, Carlos Ribeiro  
[BR/BR]; Rua Paul Bouthillier 178, Bairro Comiteco,  
30315-010, Belo Horizonte, Minas Gerais (BR). DOS  
SANTOS, Robson, Augusto, Souza [BR/BR]; Bairro  
Santa Amélia,, 31540-240 Belo Horizonte, Minas  
Gerais (BR). BOUGIS, Pierre, Edouard [FR/FR];  
18 Rue Ranque, 13001 Marseille (FR). EUCLAIR,  
Marie-France [FR/FR]; 10 Rue Ranque, 13001 Marseille

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SCORPION PEPTIDE AS HYPOTENSIVE AGENT

(57) Abstract: The present invention provides isoformes from a peptide family belonging to South American scorpion *Tityus serrulatus* that acts as hypotensive agents by potentiating Bradykinin and, therefore, can be used as anti-hypertensive drugs. A peptide was firstly isolated from *Tityus serrulatus* venom and showed a strong and long-lasting hypotensive activity when tested in rats. This peptide was first named TsHpt-I (*Tityus serrulatus Hypotensin-I*). Also, three more highly similar isoformes were identified and revealed a peptide family with very close primary structure. They were named TsHpt-II, TsHpt-III and TsHpt-IV.



WO 03/104274 A1

**SCORPION PEPTIDE AS HYPOTENSIVE AGENT**

The present invention relates to the isolation and characterization of peptides from scorpion venom, suitable for use as pharmaceutical drugs in treatment of hypertension.

**BACKGROUND - DISCUSSION OF PRIOR ART**

About 600 million people worldwide have high blood pressure and nearly 0.5 % of this total die per year as direct result of hypertension. It is well known that hypertension increases the risk of heart disease, heart attacks and strokes and yet 70% of people with hypertension are not adequately treated. According to World Health Organization (WHO) and International Society of Hypertension (ISH) it is projected that death and disability from coronary heart disease and cerebrovascular disease are rapidly increasing in developing countries and they will be ranked on top among the causes of the global burden of disease in the next twenty years. Because of the central role played by hypertension in coronary heart disease and stroke, it is claimed by WHO-ISH that one of the biggest challenges facing public health authorities and physicians is the control of hypertension. (Bulletin of the World Health Organization, 1999, 77 (3).)

Blood pressure is measured as systolic, i.e. pressure of the blood in the arteries when the heart beats, and diastolic, i.e. pressure between heartbeats. Values of blood pressure are expressed in millimeters of mercury

(mmHg) units. According to WHO-ISH the optimal blood pressure is less than 120 systolic and 80 diastolic, i.e., 120/80 mmHg, while normal blood pressure is classed as less than 130/85 mmHg. High blood pressure, or hypertension, is considered to be a pressure greater than or equal to 140/90 mmHg and "high normal" blood pressure is between 130/85 and 140/90 mmHg. Both hypertension and "high normal" blood pressure pose threat to health. (Bulletin of the World Health Organization, 1999, 77 (3).)

High blood pressure occurs when the body's smaller blood vessels (known as the arterioles) narrow, which causes the blood to exert excessive pressure against the vessel walls. The heart must therefore work harder to maintain this higher pressure. Although the body can tolerate increased blood pressure for months and even years, eventually the heart can enlarge and be damaged (a condition called hypertrophy), and injury to blood vessels in the kidneys, the brain, and the eyes can occur. Hypertension has been aptly called a silent killer, because it usually produces no symptoms (United States Patent 6,569,891. Owen, et al. May 27, 2003).

At the present time, six classes of drugs are recognized as efficient for hypertensive treatment: diuretics, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, calcium antagonists, angiotensin II antagonists and alpha-blockers. The drug of choice for a

patient treatment depends on factors such as age, ethnicity and presence of others cardiovascular conditions.

Diuretics cause the body to excrete water and salt. ACE inhibitors reduce the production of angiotensin - a peptide that constricts arteries - and reduce the degradation of bradykinin - a peptide that dilates arteries. Beta-blockers block the effects of adrenaline, thus easing the heart's pumping action and widening blood vessels. Vasodilators, expand blood vessels and calcium channel blockers help decrease the contractions of the heart and widen blood vessels.

Research now indicates that beta-blockers, diuretics, and ACE inhibitors all reduce the risk for fatal and non-fatal cardiovascular events. As first-line treatment experts generally recommend beta-blockers or diuretics, which are inexpensive, safe, and effective, for most people with hypertension who have no complicating problems (United States Patent 6,569,891. Owen , et al. May 27, 2003). Combination drug therapy can be recommended for patients whose blood pressure does not fall to optimal levels with single drug treatment.

All drugs used for hypertension have side effects, some distressing, and on-going compliance is difficult. Therefore, there is still need for novel anti-hypertensive drug classes (Bralet and Schwartz, TRENDS in Pharmacological Sciences, Vol. 22 No.3, March 2001).

Animal venoms have proved to be a valuable resource of unique and novel chemical compounds that have shown a wide variety of biological activities. Furthermore, advancements in synthetic organic chemistry have made it possible to synthesize not only newly identified natural products, but also structural analogs and semi-synthetic derivatives. Even with all the advances in synthetic organic chemistry, however, much time and effort is saved by using a model compound established through the elucidation of a novel natural product.

Isolation of natural products include, fungi, bacteria, marine organisms (sponges, snails, fishes and sea snakes) arthropods, amphibian, reptiles and the number of newly reported compounds is increasing fast. It has been estimated that more than 2,500 toxins and other natural products with biological activity have been already isolated from animal venoms (Theakston RD, Kamiguti AS. A list of animal toxins and some other natural products with biological activity. Toxicon. 2002 May;40(5):579-651.)

Scorpion venom is a peptide rich mixture with many different biological activities and is known as one of the richest sources of biologically active peptides. This reflects millions of years in evolution of specialized venom producing glands. Scorpions are among the oldest (400 million years) living groups of animals. They are represented by 1500 distinct species and their venom is a mixture of components containing about 50-100 polypeptide

toxins. Thus, about 100,000 different peptides are surmised to exist in all these species. However, only a small number of these polypeptide toxins, about 200 distinct polypeptides from 30 different species of scorpion, have  
5 been described and published to date.

Natural venoms are metabolic products not directly essential for the life of producer organism, although they are essential for both predatory and defense needs. Venom constituents can act in many fronts on the victim's tissues  
10 such as ionic channels in excitable tissues and specific receptors, like enzymes, for example, leading to disturbs in muscular, cardiovascular or respiratory systems.

The use of venoms from animal sources in prospecting new drugs candidates has increased enormously in the last  
15 decade.

The most studied and representative classes of bioactive compounds found in scorpion venoms are related to small proteins, i.e., less than 10 kDa, which bind on selective ionic channels of both invertebrates and  
20 vertebrates nervous systems. These proteins are able to block or modulate kinetics of  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Ca}^{2+}$  and  $\text{Cl}^-$  selective-channels, leading the inflicted victim to a massive neurointoxication and sometimes death. Due their selectively, scorpion toxins are classified accordingly: 1)  
25 to their toxicological spectrum; 2) to their binding sites on ionic selective channels and 3) to their structural family.

However, little is known about other classes of molecules present in scorpion venom that are not lethal and causes only micro-toxicological effects.

Peptides from animal venoms that are active as  
5 bradykinin-potentiating factors are of particular interest because of their strong effect as hypotensive agent.

To date, bradykinin-potentiating factors or bradykinin-potentiating peptides have been found in venom from the spider *Lactrodectus tredecimguttatus*, from the  
10 scorpions *Leiurus quinquestriatus*, *Tityus serrulatus*, *Buthus martensii* and *B. occitanus* and from Viparidae snakes, mainly, from the southamerican genus *Bothrops* sp.

Since such agents would be vasodilators they have potential in hypertension and any disease where tissue  
15 blood perfusion is compromised. Such indications include, but are not limited to, systemic hypertension, angina, stroke, retinal vascular diseases, claudication, Raynauds disease, diabetes, and pulmonary hypertension. (US Patent 6,573,390, Burk, 3 June 2003).

20 Peptides described as Bradykinin-like or as Bradykinin-potentiating factors are also active on insect nervous system and can, therefore, be envisaged as potential insecticides. Bradykinin related peptides have been found in many venoms of insects from Hymenoptera (ants  
25 and social wasps). Injections of these peptides into vertebrate predators may play an important role in their defense since they produce severe pain. On the other hand,

Piek and co-workers, working with Bradykinin-like peptides isolated from wasp venoms, investigated the effects of these peptides on the insect central nervous system. These kinins block in an irreversibly manner, the nicotinic synaptic transmission from the cercal nerve to a giant interneuron in the sixth abdominal ganglion of the cockroach *Periplaneta americana*, by depletion of the transmitter in the presynaptic site.

#### SUMMARY OF THE INVENTION

Peptides that form a structural family were purified from the venom of Brazilian scorpion *Tityus serrulatus*. Structurally, this family is identifiable by the absence of Cys residues and therefore with no disulfide bonds. Moreover, mature peptides from this family ranges from 2500 to 3000 Da and has typical amino acid signatures (Pro-Pro, Ala or Pro-Pro) at their carboxi-terminal extremity. Pharmacologically, these peptides act as bradykinin-potentiating peptides, and therefore, can be used as hypotensive agents. These, structural and pharmacological features, classify this peptide family as serious candidates to be used as pharmaceutical drugs in the treatment of hypertension.

#### DETAILED DESCRIPTION OF THE INVENTION

##### A. Definitions

***Tityus serrulatus*:** A Brazilian scorpion species presently classified as follows: Eukariota; Metazoa; Arthropoda, Chelicerata; Arachnida; Scorpiones; Buthoidea;



Buthidae; *Tityus*; *Tityus serrulatus*. Since this is a parthenogenetic species, i.e., a species with an asexual reproduction in which embryos develop without any fecundation, *Tityus serrulatus* has been recently placed as  
5 an all-female morph species derived from *Tityus stigmurus*, another South American scorpion species. Moreover, a sexual population of *Tityus serrulatus* was recently put on evidence on Minas Gerais State, in Brazil.

**Scorpion Venom:** A secretion produced by the venom  
10 gland located at the scorpion telson. The venom constituents, mainly proteins, are produced by the gland cells and secreted into the glandular lumen. It is used in both predatory and defense senses being toxic to many animals, for example, from insects to humans. Methods of  
15 ...venoms extraction consist on electrical or manual milking, in which the gland content is expelled and collected for further preparations. Alternatively, the whole telson or gland is "crashed" in an organic or inorganic medium and the proteins purified from the whole telson or gland  
20 extract. Crude venom or whole venom are related to the complete milked solution without any further preparation such as lyophilization or any separation step. Soluble fraction of venom is related to the venom, preferably lyophilized venom, that was resuspended on a solution,  
25 preferably a low ionic strength buffer and submitted to centrifugation to separate the soluble fraction from the solid fraction.

**Peptide:** A protein with low molecular mass. Although there is not a real bound between protein and peptide, peptides are considered, in a practical sense, as proteins smaller than 10000 Da.

5       **Liquid chromatography:** A molecular separation method consisting on a mobile phase, a solvent or a buffer, for example, passed throughout a fixed phase with particular physico-chemical properties. Molecules samples are loaded onto a cylindrical tube filled with the fixed phase and are  
10 eluted by the mobile phase being separated by means of the physico-chemical properties related to: 1) the molecules themselves; 2) the fixed phase and 3) the mobile phase. Conventional, Fast Performance Liquid Chromatography (FPLC) or High Performance (or Pressure) Liquid Chromatography  
15 (HPLC) are related to the apparatus used. Size-exclusion (or molecular filtration), Ionic (Cationic or Anionic) Exchanges and Reversed-phase (or Hydrophobicity) are related to physico-chemical properties of the fixed phase.

Inventors have made intensive and extensive studies on  
20 isolation of novel scorpion peptides from the venom gland of a scorpion *Tityus serrulatus*, on the basis of their ability to show any biological activity. As a result, the inventors have succeeded in isolation and purification of a novel peptide family, named Scorpion Hypotensive Peptides  
25 (SHptP), represented by SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4 (as described in claim 1 and claim 2), in which anti-hypertensive properties were found. They

have also succeeded in determination of the primary and higher-order structures of TsHpt-I (SEQ ID NO: 1). It has been found that native and synthetic TsHpt-I (SEQ ID NO: 1) exhibits strong ability to decrease blood pressure in rats.

5 Thus, the invention has been accomplished.

This invent are related to a family of peptides, which will be refereed as Scorpion Hypotensive Peptides (SHptP), found in scorpion venom, which have common structural and pharmacological features. The structural and  
10 pharmacological features that can be used in this peptides family identification are listed:

- i) Lack of Cystein residues and, therefore, no internal disulfide bridges;
- ii) A molecular signature at the C-terminal ending or  
15 portion, described as: Xaa-Pro-Pro and Xaa-Pro-Pro-Ala, where Xaa is any amino acid residue;
- iii) pairs of amino acid residues such as Pro-Pro, Lys-Glu, Lys-Asp, Arg-Glu, Arg-Asp, Ile-Ile, Ile-Leu, Leu-Leu, Leu-Ile, which form a protective shield against amino-, endo-  
20 and carboxi- proteinases enzymes;
- iv) Hypotensive effects using "in vivo" tests (bioassays) in vertebrates.

Native peptides, with structural and anti-hypertensive properties described above, were found in the venom of the  
25 Brazilian scorpion *Tityus serrulatus*, after fractionation of the crude venom using liquid chromatography.

Animals were collected in the Minas Gerais State, Brazil, and their venom were collected by electrical stimulus. Alternatively, manual stimulus can also be applied with the same result.

5 In a preferred manner, venom was dialysed against distilled water to eliminate salts and small peptides. After gel filtration through Sephadex G-50, samples of interest were loaded preferably onto a reverse-phase HPLC column, equilibrated with a polar acidic solvent,  
10 preferably 0.1% TFA in water (solvent A) and eluted using a gradient of a apolar solvent, preferably 0.1% TFA in acetonitrile (solvent B). The elution was measured at 230 nm and 280 nm. Collected samples was then submitted to MALDI-TOF mass spectrometry analyses. Fractions of interest  
15 were further purified, using a shallower gradient of solution B, preferably using the same reverse-phase column.

Purified peptides, as judged by reversed phase HPLC profile and mass spectrometry analyses were submitted to further investigation in order to determine their primary  
20 structure. Two main molecular species, measuring 2652.25 Da and 2724.64 Da, were identified by MALDI-TOF mass spectrometry analyses and subjected to amino acid hydrolysis and subsequent analysis, and amino acid sequencing by automated Edman's degradation. The sum of  
25 these analyses, i.e., HPLC chromatographic profiles, MALDI-TOF mass spectrometry, amino acid hydrolysis and analysis and amino acid sequencing by Edman's degradation lead us to

identify four isoforms molecules belonging to the same structural family that were named: TsHpt-I (*Tityus serrulatus* Hypotensin-I), TsHpt-II (*Tityus serrulatus* Hypotensin-II), TsHpt-III (*Tityus serrulatus* Hypotensin-III) and TsHpt-IV (*Tityus serrulatus* Hypotensin-IV), identified by the referred sequences SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4 (as described in claim 1 and claim 2).

All of the four molecules described here are linear polypeptide chains without any Cys residues and, therefore, without any internal disulfide bridge. TsHpt-I and TsHpt-II are composed by 25 amino acid residues, being the sole difference between these two chains, the amino acid in position 15, which is a Gln residue in TsHpt-I and a Glu residue in TsHpt-II. The other two molecules found, i.e., TsHpt-III and TsHpt-IV are composed by 24 amino acid residues differing from TsHpt-I and TsHpt-II by the absence of the C-terminal residue Ala. TsHpt-III and TsHpt-IV differ one from the other by the same mutation that was observed for TsHpt-I and TsHpt-II, i.e., a shift in the residue at position 15, which is a Gln in TsHpt-III sequence and a Glu in the TsHpt-IV sequence.

Peptides of the present invention, belongin to the Scorpion Hypotensive Peptides (SHptP) family, can be isolated from scorpion venoms. They may also be synthesized, chemically or by recombinant techniques from

the isolated gene encoding the peptide or its preprotein or from a synthetic or cDNA copy of the gene.

Variants, i.e. isoformes, of the peptides of the present invention may be prepared synthetically by peptide synthesis techniques, recombinantly or by cleavage from an isolated peptide of the invention, as in the case of TsHpt-III and TsHpt-IV.

Similar polypeptides can be produced by conventional site-directed mutagenesis, which is one avenue for routinely identifying residues of the molecule that can be modified without rendering the resulting polypeptide biologically inactive, or by chemical synthesis.

Nucleotides sequences encoding peptides or variants of the peptides of the present invention are also within the scope of this invention. Insect viruses and plants may be engineered to express the peptides and/or variants in a manner to render themselves as vectors, vehicles or excipients for the peptides to another organism.

It is well-known that there is substantial redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences which contain alternative codons which code the identical amino acid. For purposes of this specification, a sequence beating one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are variations in the DNA sequence which do not alter the ultimate physical properties of the

expressed protein. (US Patent 5,494,895, Garcia, et al., 27 February 1996)

This invention also concerns chemical modification of the peptides of the present invention. Although native  
5 peptides described by this invention did not show any post-translational modification as, for instance, acetylation, deamidation, pyroglutamic acid formed from Gln, C-terminal amide formed from Gly, methylation, phosphorylation, and others, such modifications of the native, synthesized or  
10 recombinant peptides may be achieved. These modifications may be important to protect peptides from enzymatic degradation leading to an extended half-life of peptides used as drugs.

This invention also concerns to the anti-hypertensive  
15 properties of Scorpion Hypotensive Peptides (SHptP) family and the application of peptides belonging to SHptP family as hypotensive agents in pharmaceutical applications for hypertension treatments and purposes.

TsHpt-I were found to be able to potentiate bradykinin  
20 effects in a strong and long-lasting manner.

Bioassays using waked and anesthetized rats showed that the potentiating unit of TsHpt-I was 10 µg. At this dose TsHpt-I was able to double the activity of a single dose of bradykinin for almost 20 minutes in anesthetized  
25 animals.

## EXAMPLES

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the casual variations, adaptations, modifications, deletions or additions of procedures and protocols described herein, as come within the scope of the following claims and its equivalents. Therefore, it is to be understood that the present invention is not limited to the examples.

## EXAMPLE 1

Fractionation of *Tityus serrulatus* venom and purification of peptides

Venom of *Tityus serrulatus* scorpion, captured in the wild, in the Minas Gerais State, Brazil, or raised in the laboratory, preferably soluble fraction, is used to isolation of peptides belonging to TsHpt family.

Fractionation of the venom is carried out on a liquid chromatography system preferably as follows: soluble fractions are submitted to a dialysis against distilled water (24 h, 4°C, 1 liter x 5, using Spectrapor 3 membrane with a mol. wt. cut-off < 1000). After, the dialyzed solution is recovered and applied onto a conventional size-exclusion (Superdex G50) liquid chromatography system and eluted with water and acetic acid. Alternatively, venom can be fractionated directly on a HPLC or FPLC system using reverse-phase C4 or C18 column. The yield is separated in



different pools according to the separation profile. Peptides with molecular mass in the range of 2000 to 3000 are normally found spread out in all collected pooled fractions.

5 Further purification of peptides is carried out preferably on HPLC system with a reverse-phase C4 or C18 column and eluted by a gradient using a non-polar solvent. Mobile phases (solutions) are preferably: A) Trifluoroacetic acid (TFA) 0.1 %, v/v, in pure grade water .  
10 and B) TFA 0.1 %, v/v in Acetonitrile. Lyophilized samples are dissolved in solution A and load onto column (RP-C18) using a solution A flow at 1mL/minute, preferably. Gradient is achieved by introducing solution B, preferably at 0.01 to 1 % by minute. Elution profile is monitored by  
15 absorbance at 210-230 nm. Proteins eluted can also be monitored by mass spectrometry analyses. Alternatively ionic changes columns can be used using any liquid chromatography system.

Commonly, fraction III, issued from previously  
20 Sephadex® G50 was loaded (575 Dg) onto a reverse-phase HPLC column (Merk 100 RP-18, 4x250 mm, Lichrospher, 5µm), equilibrated with 0.1% TFA (solvent A) and eluted (1.0 ml/min) in gradient of solvent B (0.1% TFA in acetonitrile) using a ratio of 0.33% B/min. The elution was measured at  
25 230 nm and 280 nm. Collected samples (1.0 ml each) was then submitted to MALDI-TOF analysis. Fractions of interest were found at a retention time between 72 to 91 minutes and were

further purified, using a shallower gradient (0.1% B/min) at the same reverse-phase column.

## EXAMPLE 2

Chemical characterization of peptides - determination of  
5 structure of peptides

After isolation from semi purified fractions, two samples containing: i) a peptide with an observed molecular mass of 2652.25 Da and ii) a peptide with an observed molecular mass of 2724.64 Da were submitted to amino acid  
10 analysis and sequencing as described: Lyophilized samples (1 nmol) were submitted to acidic hydrolysis under N<sub>2</sub> atmosphere at 110° C by 24 or 72 hours using a Pico-Tag™ work-station (Millipore/Waters Associates). After hydrolysis, samples were analyzed on a Beckman 6300  
15 apparatus. To amino acid sequencing, native peptides (1 nmol) were submitted to Edman automated sequencing using an Applied Biosystems 476A sequencer.

MALDI-TOF mass spectrometry analyses were performed on a Voyager-DE™RP BioSpectrometer Workstation (PerSeptive  
20 Biosystems, Framingham, MA, USA) in the positive linear mode. Protein solutions (0.5 µL of sample, variable concentrations) were spotted onto the target, followed by 0.5 µL of CHCA (α-cyano-4-hydroxycinnamic acid) matrix solution (60% acetonitrile/0.3% TFA), and allowed to dry at  
25 room temperature (dried-droplet method). A 337 nm nitrogen laser was used to desorb the samples. Mass spectra were obtained from the average of 256 laser pulses from m/z 600

to 39,400. In MALDI-TOFMS experiments, external calibration of the mass scale was performed using a standard polypeptide mixture (Sequazyme Peptide Mass, Perseptive Biosystems). Known toxins from *Tityus serrulatus* venom were  
5 also used in some cases as standard references for internal multipoint calibration. Data processing was performed with the GRAM/386 software.

Edman degradation of peptide with molecular mass of 2652.25 Da showed a linear peptide with 24 residues,  
10 without any C residues. The calculated monoisotopic mass for the sequence obtained from automated Edman's degradation was 2652.40 Da. Sequencing of peptide with an observed molecular mass of 2724.64 Da showed the same sequence as the previously described peptide, except for  
15 the additional Ala residua at C-terminus and for the position 15, in which two different residues (Gln and Glu) were identified. This mutation, i.e. Gln to Glu, leads to a 1 Da difference that could not be distinguishable on both HPLC and mass spectrometry analyses. The calculated  
20 molecular mass varied from 2723.44 Da, in the Gln15 isoform, to 2724.42 Da in the Glu isoform and mass spectrometry analyses showed an observed mass of 2724.64 Da.

### EXAMPLE 3

25 Circular dichroism (CD) analyses of TsHpt-I

The CD spectra acquisitions were performed in a JOBIN-IVON CD6, with  $\lambda$ 178-260 and an analysis time of 30 seconds/nm,  $\epsilon$  1 mm.

Samples of TsHpt-I (200  $\mu$ g) were diluted in 200  $\mu$ L of  
5 pure grade water, phosphate buffer 50 mM, or in different concentrations of trifluoroethanol (TFE) as follows: 12.5, 25, 50 and 90%.

Spectra showed that this peptide secondary structure is predominantly random coiled. Increasing in band at 220  
10 nm in solutions of higher concentrations of TFE indicates that an alpha-helix structure can be formed at hydrophobic environment.

#### EXAMPLE 4

The peptide related to the invention, TsHpt-I, could  
15 also be obtained by Fmoc chemical synthesis. The TsHpt-I obtained has the same chromatographic properties as the native molecule. The mass measured of the synthetic peptide was 2723.12 Da and is very similar to the calculated monoisotopic mass of 2723.44 Da. The synthetic molecule has  
20 the same hypotensive activity as the native molecule as assessed by biological assays on rats.

#### EXAMPLE 5

Biological Activity Data - Anti-hypertensive properties of Scorpion Hypotensive Peptides (SHptP) family

25 Wistar rats, weighting  $300 \pm 20$  g were used, waked or anesthetized, to assess the hypotensive properties of peptides. Bradykinin (Bachem, Co) and TsHpt-I were

dissolved in sterile isotonic saline (0.9% NaCl) immediately before use.

"In vivo" experiments using waked animals: a day before the experiment, rats were anesthetized with ether and a polyethylene catheter (PE-10 connected to PE-50) was inserted into the abdominal aorta through the femoral artery for blood pressure measurements. For intravenous injections, a polyethylene cannula was implanted into the femoral vein. Arterial blood pressure and heart rate were monitored by a solid-state strain-gauge transducer. All variables were recorded continuously on a computer through a data acquisition system, Biopac®, and processed by the Acknowledge® software.

Bradykinin, 1µg or 2µg, was injected and the response measured as variation on average arterial pressure. Hypotensive effect of TsHpt-I (10 µg) alone was measured after Bradykinin. The hypotensive effect of bradykinin (1µg) was then re-evaluated after 5 and 10 minutes following the injection of TsHpt-I.

"In vivo" experiments using anesthetized rats: the arterial blood pressure and heart rate were monitored continuously after insertion of catheters as described above. Rats were previously anesthetized with urethane, 1.2 mg/kg, (via i.p.).

The hypotensive effect of intravenous injections of bradykinin, 1µg or 2µg was measured, followed by the

measurement of hypotensive effect of TsHpt-I (10 µg). The hypotensive effect of the bradykinin (1 µg) was then re-evaluated after 1, 5, 10, 15, 20 and 30 minutes.

The potentiating unit - i.e., the amount of peptide  
5 that is able to double the activity of a single dose of bradykinin - of TsHpt-I was 10 µg. At this dose TsHpt-I was able to double the activity of a single dose of bradykinin for almost 20 minutes in anesthetized animals.

Therefore, this invention provides the possibility of  
10 using new molecules and formulations to treat hypertension.

These peptides, and their possible variants, are small, relatively simple and inexpensive to construct and can help to enlarge the knowledge and the use of peptides as medicaments.

15 While the above description contains many specificities, these should not be construed as limitations on the scope of the invention, but rather as an exemplification of one preferred embodiment thereof.

Other variations are possible such as, for example,  
20 the use of bradykinin-potential peptides in synergy with bradykinin-like peptides that act on insect nervous system to envisage a new biological insecticide.

Another example is related to genetically engineered virus, microorganisms and plants to be used as vectors,  
25 vehicles or excipients for the peptides to another organism, for drug administration or insecticidal purposes.

Genes encoding the hypotensive effective peptides according to the present invention can be introduced into a plant by genetic engineering techniques, which upon production of the peptide in the plant cell is expected to  
5 be useful as a means for administrable drug. Therefore, it is possible to use a plant cell as excipient or vector.

It is necessary, however, that the genetic sequence coding for the peptide be expressed and produced as a functional peptide in the resulting plant cell or modified  
10 organism. It is believed that DNA from both genomic DNA and cDNA and synthetic DNA encoding an effective peptide may be used for transformations. Further, a gene may be constructed partially of a cDNA clone, partially of a genomic clone or partially of a synthetic gene and various  
15 combinations thereof. In addition, the DNA coding for a peptide gene may comprise portions from various species other than from the source of the isolated peptide.

Methods to produce virus, microorganisms and plants expressing foreign genes are known. (US Patent 5,441,934,  
20 Krapcho, et al., 15 August 1995)

Accordingly, the scope of the invention should be determined not by the embodiments illustrated, but by the appended claims and their legal equivalents.

## Claims

1. Four isolated isoformes of peptide, with anti-hypertensive properties, named as TsHpt-I (*Tityus serrulatus* Hypotensin-I), TsHpt-II (*Tityus serrulatus* Hypotensin-II), TsHpt-III (*Tityus serrulatus* Hypotensin-III) and TsHpt-IV (*Tityus serrulatus* Hypotensin-IV), and refereed as listed sequences SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4.

2. Other peptides from scorpions (presently taxonomic classification as follows: Eukariota; Metazoa; Arthropoda, Chelicerata; Arachnida; Scorpiones) belonging to the same pharmacologically active and structurally peptide family, characterized by two or more following features: i) lack of Cystein residues and, therefore, no internal disulfide bridges; ii) a molecular signature at the C-terminal ending or portion, described as: Xaa-Pro-Pro and Xaa-Pro-Pro-Ala, where Xaa is any amino acid residue; iii) pairs of amino acid residues such as Pro-Pro, Lys-Glu, Lys-Asp, Arg-Glu, Arg-Asp, Ile-Ile, Ile-Leu, Leu-Leu, Leu-Ile, which form a protective shield against amino-, endo- and carboxi-proteinases enzymes; iv) Hypotensive effects using "in vivo" tests (bioassays) in vertebrates. This family of scorpion peptides will be refereed hereinbelow as Scorpion Hypotensive Peptides (SHptP).

3. Synthetic peptides comprising complete, partial or modified sequences of claim 1 and/or molecular signatures of claim 2.



4. A nucleic acid molecule that codify for peptides of claim 1 and/or peptide family of claim 2.

5. Isolated and purified peptides of claim 1 and/or claim 2 wherein peptides are produced by recombinant techniques using any virus system, any bacterial system, any fungal system or any other prokaryotic or eukariotic system or combination thereof.

6. A method for producing any administrable pharmaceutical composition comprising the complete, partial or modified amino acid sequences of claim 1 and claim 2.

7. A method for producing any genetically modified virus, bacteria, fungi, plant or any other recombinant techniques using any virus system, any bacterial system, any fungal system or any other prokaryotic or eukariotic system or combination thereof, in order to use these organisms as excipient or vector for complete, partial or modified sequences of claim 1 and/or claim 2.

8. A pharmaceutical composition comprising an anti-hypertensive amount of peptides of claim 1.

9. A method for labeling and/or chemically modifying peptides of claim 1 and claim 2.

..

### SEQUENCE 1:

Lys-Gln-Ile-Lys-Glu-Thr-Asn-Ala-Lys-Pro-Pro-Ala  
15 20 25

TYPE: Protein

NAME: TsHpt-I

CELL LOCALIZATION: Secreted

Ala-Glu-Ile-Asp-Phe-Ser-Gly-Ile-Pro Glu-Asp-Ile-Ile-  
1                    5                    10

LENGTH: 25

ORGANISM: *Tityus serrulatus*

**BIOLOGICAL ACTIVITY:** Hypotensive peptide

**CELL LOCALIZATION:** Secreted

**SEQUENCE 3:**

Ala-Glu-Ile-Asp-Phe-Ser-Gly-Ile-Pro-Glu-Asp-Ile-Ile-

1

5

10

Lys-Gln-Ile-Lys-Glu-Thr-Asn-Ala-Lys-Pro-Pro

15

20

24

LENGTH: 24

TYPE: Protein

ORGANISM: *Tityus serrulatus*

NAME: TsHpt-III

BIOLOGICAL ACTIVITY: Hypotensive peptide

CELL LOCALIZATION: Secreted

**SEQUENCE 4:**

Ala-Glu-Ile-Asp-Phe-Ser-Gly-Ile-Pro-Glu-Asp-Ile-Ile-

1

5

10

Lys-Gln-Ile-Lys-Glu-Thr-Asn-Ala-Lys-Pro-Pro

15

20

24

LENGTH: 24

TYPE: Protein

ORGANISM: *Tityus serrulatus*

NAME: TsHpt-IV

BIOLOGICAL ACTIVITY: Hypotensive peptide

CELL LOCALIZATION: Secreted

Type

- i) SEQUENCE NUMBER 2 (TsHpt-II): Ala-Glu-Ile-Asp-Phe-Ser-Gly-Ile-Pro-Glu-Asp-Ile-Ile-Lys-Glu-Ile-Lys-Glu-Thr-Asn-Ala-Lys-Pro-Pro-Ala

- ii) SEQUENCE NUMBER 3 (TsHpt-III): Ala-Glu-Ile-Asp-Phe-Ser-Gly-Ile-Pro-Glu-Asp-Ile-Ile-Lys-Gln-Ile-Lys-Glu-Thr-Asn-Ala-Lys-Pro-Pro
- iii) SEQUENCE NUMBER 4 (TsHpt-IV): Ala-Glu-Ile-Asp-Phe-Ser-Gly-Ile-Pro-Glu-Asp-Ile-Ile-Lys-Glu-Ile-Lys-Glu-Thr-Asn-Ala-Lys-Pro-Pro

## INTERNATIONAL SEARCH REPORT

International Patent No.  
PCT/BR 03/00073-0

## CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup>: C07K 14/435; A61K 38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>7</sup>: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REGISTRY, CAPLUS, MEDLINE, WPI, EPO, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| A        | S. V. SAMPAIO et al., "Further characterization of toxins T1IV (TsTX-III) and T2IV from tityus serrulatus scorpion venom", Toxicon, Vol. 29, No. 6, 1991, pages 663-672<br><i>the whole document.</i>   | 1,8                   |
| A        | E. C. ARANTES et al., "Isolation and characterization of TsTX-V, a new neurotoxin from tityus serrulatus scorpion venom which delays the inactivation of NA <sup>+</sup> channels", Biochimica et Biophysica Acta, 1199, 1994, pages 69-75;<br><i>the whole document.</i> | 1,8                   |
| A        | A. P. CORRADO et al., "The mechanism of the hypertensive effect of brazilian scorpion venom (tityus serrulatus lutz e mello); Toxicon, 12, 1974, pages 145-150;<br><i>the whole document.</i>   | 1,8                   |

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

## \* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&amp;“ document member of the same patent family

Date of the actual completion of the international search

20 August 2003 (20.08.2003)

Date of mailing of the international search report

23 September 2003 (23.09.2003)

Name and mailing address of the ISA/AT

Austrian Patent Office

Dresdner Straße 87, A-1200 Vienna

Facsimile No. 1/53424/535

Authorized officer

WENIGER S.

Telephone No. 1/53424/341

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/BR 03/00073-0

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 2-7 and 9  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 2-7 and 9  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
The subject matter of claim 2 relates to a huge number of "other peptides" described by 4 different categories of "characterizing" features, lacking any clear and concise description (moreover - due to the addition of the last sentence - not fulfilling the formal requirements of a patent claim);  
see supplemental sheet
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Claim 1 relates to four structurally different peptides not being characterized by any common inventive feature. Thus claim 1 and dependent claim 8, each, comprise 4 groups of inventions:

Group I, directed to a peptide of SEQ ID NO: 1  
Group II, directed to a peptide of SEQ ID NO: 2  
Group III, directed to a peptide of SEQ ID NO: 3  
Group IV, directed to a peptide of SEQ ID NO: 4

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**SUPPLEMENTAL SHEET**

Claim 3 is even more undefined as claim 2, thus not being searchable since its subject matter is not even to be guessed.

Claims 4 and 5 exceed the disclosure of the present application because the isolation and/or preparation of a "certain" nucleic molecule coding (and not "codifying"!) for peptides of claim 1 or a peptide family of claim 2 according to claim 4 cannot be considered to lay within the scope of disclosure of the present application and the production of vaguely determined expression systems as mentioned in claim 5 clearly exceed the scope of disclosure, as well.

Claim 6 relates to a method of producing an administrable pharmaceutical composition, not characterized by a single feature concerning a production/process step.

Claim 7 lacks any technical features which could be suited to characterize its subject matter in a clear and concise manner.

Claim 9 relates to a vague and totally undetermined method of labeling or chemically modifying peptides not characterized by any technical feature which could be considered to be characteristic, clear or concise.